Vernalis'V15886 fails to meet primary endpoint and seeks partnering on further development

20 August 2015

UK biotech company Vernalis (LSE: VER) has announced a failure to meet the primary endpoint of its study on V158866 but intends to partner on any further clinical development.

The Phase II proof-of-concept study of V158866, a fatty acid amide hydrolase inhibitor, was investigating the therapy as a treatment for neuropathic pain as a result of spinal cord injury. The randomized, double-blind, placebo-controlled, two-period crossover study resulted in elevated endocannabinoid levels, but failed to meet its pain reduction primary endpoint on an intent-to-treat basis.

Vernalis does not plan to make any further investment in the program and will seek to partner on the therapy, as a Phase I study provided “encouraging” data in evaluating the safety, tolerability and pharmacokinetic effects of the compound.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK